文献速递胃肠动力与功能性疾病

肠易激综合征中短链脂肪酸富集代谢型的临床相关性

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance.
PubMed 文献 · Aliment Pharmacol Ther · 2026-04-17

该研究对中重度腹泻型肠易激综合征(IBS-D)患者基线数据行横断面探索性分析,通过粪便挥发性有机化合物谱识别出短链脂肪酸(SCFA)富集代谢型,占31.7%(20/63),并与更严重腹痛、便急、排便频率增加及全肠道传输加快相关。

要点

  • 中重度IBS-D患者中可识别出SCFA富集代谢型,占31.7%(20/63)。
  • SCFA富集代谢型与更严重腹痛、便急、排便频率增加及全肠道传输加快相关。
  • SCFA相对丰度与症状严重度正相关、与传输时间负相关。

核心结论

  • 粪便SCFA富集代谢型与以疼痛、便急、快速传输和排便频率增高为特征的IBS-D表型相关。

研究设计与样本

  • 为多中心随机安慰剂对照昂丹司琼治疗IBS-D试验(TRITON)基线数据的post hoc横断面探索性分析。
  • 粪便挥发性有机化合物采用GC-MS分析,微生物组采用全基因组鸟枪法宏基因组测序。
  • 采用无监督层次聚类识别SCFA富集代谢型,并用非负矩阵分解(NMF)推导代谢特征。

主要发现

  • 63名参与者中20名(31.7%)被识别为SCFA富集代谢型。
  • 该代谢型与更严重腹痛、便急、排便频率增加及更快全肠道传输相关。
  • NMF识别出三种代谢特征:S3以高比例SCFA为特征并对应SCFA富集代谢型,S1和S2对应非SCFA(Other)代谢型。
  • SCFA相对丰度与症状严重度正相关,与传输时间负相关。
  • Other代谢型及S1/S2特征富集与较慢传输相关的分类群,S3与SCFA代谢型无重叠分类群。

临床怎么用

  • 对中重度IBS-D患者可关注SCFA富集代谢型,其与更重症状及更快传输相关,或有助于表型分层。

局限性

  • 为post hoc横断面探索性分析,样本量有限(63例),不能推断因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolomic analysis in irritable bowel syndrome (IBS) has identified metabotypes enriched in faecal short-chain fatty acids (SCFAs), but it remains unclear whether this reflects rapid colonic transit or if these metabolites actively contribute to pathophysiology. AIMS: We aimed to determine whether an SCFA metabotype could be identified within a cohort of patients with moderate-severe IBS-D and assess whether this metabotype associated with greater clinical severity, alterations in gut transit time and specific microbiome features. METHODS: This was a post hoc cross-sectional exploratory analysis of baseline data from the multicentre, randomised, placebo-controlled trial of ondansetron in IBS-D (TRITON: ISRCTN17508514). Faecal volatile organic compounds were profiled by GC-MS. The microbiome was characterised by whole-genome shotgun metagenomic sequencing. Unsupervised hierarchical clustering was used to identify an SCFA-enriched metabotype and non-negative matrix factorisation (NMF) enabled the derivation of complementary metabosignatures by assessing continuous gradients in metabolite composition. RESULTS: A SCFA-enriched metabotype was identified in 20/63 participants (31.7%). This metabotype was associated with more severe abdominal pain, urgency, increased stool frequency and faster whole-gut transit. NMF identified three metabosignatures: S3 was typified by a high proportion of SCFAs and captured the SCFA-enriched metabotype, while S1 and S2 corresponded to the non-SCFA ("Other") metabotype. SCFA relative abundance positively correlated with symptom severity and inversely correlated with transit time. The Other metabotype and S1/S2 signatures were enriched in taxa linked to slower transit, whereas S3 showed no overlapping taxa with the SCFA metabotype. CONCLUSION: A faecal metabotype enriched in SCFAs associated with an IBS-D phenotype characterised by pain, urgency, rapid transit and higher stool frequency.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Conley TE, Duncan A, Modasia A, et al. The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance. Aliment Pharmacol Ther. 2026. PMID: 41995478. doi:10.1111/apt.70677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。